Vancouver, BC — October 31, 2025 — Leads & Copy — Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) provides a corporate update outlining strategic objectives for the upcoming year, following CEO Thomas O’Shaughnessy’s appearance on Cboe Canada’s Investor Spotlight, where he discussed enhancing cancer treatment technologies through innovation, AI-driven research, and strategic growth initiatives.
Onco has achieved milestones including acquiring Inka Health AI, moving its stock listing to the Cboe Canada Market, partnering with Dalton Pharma Services, collaborating with the University of Alberta and the Cross Cancer Institute, and signing an agreement with Nucro-Technics and Avance Clinical Pty Ltd, all furthering Onco’s research and development efforts.
Onco is focused on advancing its programs toward clinical evaluation and strengthening its position in capital markets, laying groundwork for a Phase 1 clinical trial in 2026 to transition from preclinical research to clinical translation. The company plans to pursue a U.S. strategy that focuses on enhancing the company’s U.S. presence, including a U.S. stock exchange cross-listing in 2026, which could expand access to investors and strengthen engagement with the North American research and development community.
Thomas O’Shaughnessy, CEO of Onco-Innovations, stated that the company is moving decisively into clinical development, with near-term priorities including completing steps for the first-in-human trial and advancing its U.S. strategy.
About Onco-Innovations Limited: Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco’s mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions, securing an exclusive worldwide license to patented technology that targets solid tumours.
Thomas O’Shaughnessy, Chief Executive Officer, Tel: + 1 888 261 8055, investors@oncoinnovations.com
Source: Onco-Innovations Limited
